FDA plans panel meeting to discuss vector-based gene therapy
This article was originally published in Scrip
The US FDA's cellular, tissue and gene therapies advisory committee will meet on 19 November to discuss recommendations for testing of replication-competent retrovirus/lentiviral vector-based gene therapy products, according to a notice in the Federal Register.